Form 4: Vir Biotechnology EVP Jason O'Byrne Reports Acquisition of Restricted Stock Units and Stock Options

EVP and Chief Financial Officer of Vir Biotechnology, Jason O'Byrne, reports the acquisition of restricted stock units and stock options.

Summary

• Jason O'Byrne, EVP & Chief Financial Officer of Vir Biotechnology, filed a Form 4 on February 25, 2025, reporting transactions from February 22, 2025.
• The transactions include the acquisition of 40,000 shares of Common Stock and 80,000 stock options.
• The stock options have an exercise price of $9.57, with 25% vesting on February 22, 2026, and the remainder vesting in 36 equal monthly installments.
• Following the reported transactions, O'Byrne beneficially owns 115,000 shares of Common Stock and 80,000 stock options.
• O'Byrne also has a Power of Attorney designating individuals to execute and file forms on his behalf related to Section 16 of the Securities Exchange Act of 1934 and Rule 144 under the Securities Act of 1933.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to executive compensation, and does not contain information that would significantly impact sentiment positively or negatively.

Positives

• The acquisition of restricted stock units and stock options aligns O'Byrne's interests with those of the company and its shareholders.
• The vesting schedule of the stock options incentivizes long-term performance.

Future Outlook

NA

Industry Context

This filing is a routine disclosure related to executive compensation and ownership in a publicly traded company. It is standard practice for officers to receive stock options and restricted stock units as part of their compensation packages.

Comparison to Industry Standards

• Stock option grants and restricted stock units are common compensation components for executives in the biotechnology industry, aligning their interests with shareholder value.
• Vesting schedules, like the one described (25% after one year, then monthly), are typical for incentivizing long-term commitment.
• Comparing the size of the grant to similar companies (e.g., Moderna, BioNTech) would require analyzing their executive compensation packages.

Stakeholder Impact

• The reported transactions may have a minor positive impact on shareholder sentiment as they demonstrate the executive's commitment to the company.
• The transactions have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates